Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.
Myrto K MoutafiGeorgia-Angeliki KoliouGeorgios PapaxoinisPanagiota EconomopoulouIoannis KotsantisMaria GkotzamanidouMaria AnastasiouDimitrios PectasidesEfthymios KyrodimosAlexander G DelidesEvangelos I GiotakisNikolaos G PapadimitriouIoannis G PanayiotidesChristos PerisanidisAileen I FernandezVasiliki XirouChristos PouliosEleni GagariVesal YaghoobiNiki GavrielatouSaba ShafiThazin Nwe AungAndromachi KougioumtzopoulouVasileios KoulouliasKonstantinos PalialexisStavros GkolfinopoulosAreti StratiEvi S LianidouGeorge FountzilasDavid L RimmPeriklis G FoukasAmanda PsyrriPublished in: Cancer research communications (2023)
Our WOO study demonstrates that preoperative olaparib results in a reduction in Ki67, upregulation of PD-L1 CPS, and induction of protumor features of macrophages in HNSCC.